Biotech Archives - Page 96 of 795

3 minute read

Aileron Therapeutics And Pulmonary Care Experts To Discuss The Potential Implications Of LTI-03 For Idiopathic Pulmonary Fibrosis In Virtual Key Opinion Leader Event

February 15, 5:40 PM

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis

ALRN

2 minute read

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial; Of The First 700 Patients Enrolled In Catalyst, 24% Were Identified As Having Hypercortisolism

By Benzinga Newsdesk

February 15, 5:25 PM

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by

CORT

2 minute read

T2 Biosystems Announces Commercial Expansion Through Distributors In Europe And Asia

By Benzinga Newsdesk

February 15, 5:21 PM

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of territory exclusive distribution agreements for new

TTOO

2 minute read

Taysha Gene Therapies Provides Update On Deprioritized Pipeline Programs

By Benzinga Newsdesk

February 15, 5:21 PM

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ("Taysha" or "the Company"), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of

TSHA

3 minute read

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?

By Vandana Singh

February 15, 4:29 PM

Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

ALNY

2 minute read

Why Is Rare Disease-Focused Applied Therapeutics Stock Trading Higher Today?

By Vandana Singh

February 15, 4:25 PM

Results of Applied Therapeutics' Phase 3 INSPIRE trial for oral govorestat (AT-007). Govorestat demonstrates significant sorbitol reduction, improving mobility and overall well-being in SORD Deficiency patients.

APLT

2 minute read

Monte Rosa Therapeutics’ AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst

By Vandana Singh

February 15, 3:05 PM

Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.

GLUE

2 minute read

Alnylam Earlier Announced Updates To The Statistical Analysis Plan For The HELIOS-B Phase 3 Study Of Vutrisiran; Will Include Updates To The Primary And Secondary Endpoint Structure; Topline Results Are Expected To Be Available In Late June Or Early Ju…

By Benzinga Newsdesk

February 15, 1:09 PM

R&D HighlightsAlnylam announces today updates to the statistical analysis plan for the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy. These will include updates to the

ALNY

3 minute read

UK Becomes First Major Market for Eli Lilly’s Mounjaro Prefilled Pen For Tackling Obesity

By Vandana Singh

February 15, 11:09 AM

Eli Lilly's popular obesity and diabetes drug, Mounjaro (tirzepatide), hits the UK market this week. Superdrug and Simple Pharmacy offer accessible prescriptions for NHS and private patients.

LLY

2 minute read

Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback

By Vandana Singh

February 15, 10:51 AM

Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated.

AUPH